Company Poolbeg Pharma PLC

Equities

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 10:05:08 06/03/2026 pm IST			5-day change	1st Jan Change
4.200 ^GBX	0.00%		-6.67%	+5.00%

26/12	Certain Ordinary Shares of Poolbeg Pharma PLC are subject to a Lock-Up Agreement Ending on 26-DEC-2025.	CI
08/12	Poolbeg Pharma plc Announces the POLB 001 Trial Is to Feature in Cancer Immunotherapy-Induced CRSResearch Programme	CI

Business description: Poolbeg Pharma PLC

Poolbeg Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The Company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases.

Number of employees: 16

Sales by Activity: Poolbeg Pharma PLC

Fiscal Period: December	2021 (GBP)	2022 (GBP)	2023 (GBP)	2024 (GBP)

See all business segments

Geographical breakdown of sales: Poolbeg Pharma PLC

Fiscal Period: December	2021 (GBP)	2022 (GBP)	2023 (GBP)	2024 (GBP)

See all geographic segments

Executive Committee: Poolbeg Pharma PLC

Manager	Title	Age	Since
Jeremy Skillington CEO	Chief Executive Officer	55	01/05/2021
Ian O'Connell DFI	Director of Finance/CFO	39	01/01/2021
Laura Maher CTO	Chief Tech/Sci/R&D Officer	-	08/01/2024
Carol Dalton IRC	Investor Relations Contact	-	01/01/2021
Bruno Speder LAW	General Counsel	-	01/07/2022

See POOLBEG PHARMA PLC governance

Composition of the Board of Directors: Poolbeg Pharma PLC

Director	Title	Age	Since
Luke O'Neill BRD	Director/Board Member	62	-
Jeremy Skillington BRD	Director/Board Member	55	01/05/2021
Cathal Friel CHM	Chairman	61	01/09/2020
Brendan Buckley BRD	Director/Board Member	75	24/05/2023
Ian O'Connell BRD	Director/Board Member	39	20/05/2021
Eddie Gibson BRD	Director/Board Member	52	01/07/2021

Composition of the Board of Directors

Shareholders: Poolbeg Pharma PLC

Name	Equities	%	Valuation
Cathal Friel 5.912 %	4,12,19,757	5.912 %	2 M p
IG Markets Ltd. 3.883 %	2,70,73,000	3.883 %	2 M p
Schroder Investment Management Ltd. 3.585 %	2,49,94,777	3.585 %	2 M p
Hargreaves Lansdown Fund Managers Ltd. 3.338 %	2,32,76,000	3.338 %	1 M p
KW Investment Management Ltd. 1.888 %	1,31,66,000	1.888 %	794 963 p

List of POOLBEG PHARMA PLC shareholders

Company details: Poolbeg Pharma PLC

Poolbeg Pharma Plc

40 Bank Street

E14 5NR, London

http://www.poolbegpharma.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
POOLBEG PHARMA PLC	0.00%	-6.67%	+35.48%	-55.08%	3.97Cr
ARGENX SE	-0.61%	-5.35%	+12.03%	+92.93%	4.42TCr
WUXI APPTEC CO., LTD.	+0.92%	-4.81%	+49.26%	+14.90%	4.05TCr
INSMED INCORPORATED	-2.40%	-6.16%	+87.11%	+608.08%	3.02TCr
BIONTECH SE	-0.44%	-7.92%	-6.69%	-21.33%	2.55TCr
WUXI BIOLOGICS (CAYMAN) INC.	+2.54%	-9.65%	+53.01%	-34.70%	1.92TCr
GENMAB A/S	-2.62%	-6.49%	+4.16%	-31.60%	1.65TCr
AKESO, INC.	+5.20%	+0.37%	+47.19%	+154.57%	1.26TCr
SUMMIT THERAPEUTICS INC.	+1.14%	-8.92%	-15.02%	+994.93%	1.17TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.43%	-0.31%	+55.98%	-	1.15TCr
Average	+0.82%	-5.23%	+32.25%	+191.41%	2.12TCr
Weighted average by Cap.	+0.29%	-5.16%	+33.69%	+174.36%